Demographic and clinical characteristics of patients with neuroendocrine cervical carcinoma*
| Characteristic | Overall cohort (n=453) | Early-stage disease (n=133) | Locally advanced disease (n=226) | Advanced disease (n=94) | P value |
| Age (years), median (range) | 38 (21–93) | 36 (22–72) | 38 (21–93) | 44 (24–75) | <0.0001 |
| Age at diagnosis (years) | |||||
| <30 | 75 (16.6) | 26 (19.5) | 41 (18.1) | 8 (8.5) | 0.003 |
| 30–39 | 172 (38.0) | 61 (45.9) | 82 (36.73 | 29 (30.9) | |
| 40–49 | 99 (21.9%) | 27 (20.3) | 48 (21.2) | 24 (25.5) | |
| 50–59 | 67 (14.8%) | 16 (12.0) | 36 (15.9) | 15 (16.0) | |
| 60–69 | 27 (6.0%) | 2 (1.5) | 12 (5.3) | 13 (13.8) | |
| 70–79 | 12 (2.6%) | 1 (0.8) | 6 (2.7) | 5 (5.3) | |
| ≥ 80 | 1 (0.2) | 0 (0.0) | 1 (0.4) | 0 (0.0) | |
| BMI (kg/m2) median (range) | 26.2 (14.4–77.1) | 25.5 (15.9–45.9) | 26.1 (14.4–64.8) | 28.9 (15.5–77.1) | 0.0187 |
| FIGO 2018 stage | |||||
| IA1 | 7 (1.5) | 7 (5.3) | 0 (0.0) | 0 (0.0) | <0.0001 |
| IA2 | 8 (1.8) | 8 (6.0) | 0 (0.0) | 0 (0.0) | |
| IB | 1 (0.2) | 1 (0.8) | 0 (0.0) | 0 (0.0) | |
| IB1 | 76 (16.8) | 76 (57.1) | 0 (0.0) | 0 (0.0) | |
| IB2 | 35 (7.7) | 35 (26.3) | 0 (0.0) | 0 (0.0) | |
| IB3 | 46 (10.2) | 0 (0.0) | 46 (20.4) | 0 (0.0) | |
| IIA1 | 5 (1.1) | 5 (3.8) | 0 (0.0) | 0 (0.0) | |
| IIA2 | 5 (1.1) | 0 (0.0) | 5 (2.2) | 0 (0.0) | |
| IIB | 19 (4.2) | 0 (0.0) | 19 (8.4) | 0 (0.0) | |
| IIIB | 5 (1.1) | 0 (0.0) | 5 (2.2) | 0 (0.0) | |
| IIIC1r | 54 (11.9) | 0 (0.0) | 54 (23.9) | 0 (0.0) | |
| IIIC1p | 58 (12.8) | 0 (0.0) | 58 (25.7) | 0 (0.0) | |
| IIIC2r | 26 (5.7) | 0 (0.0) | 26 (11.5) | 0 (0.0) | |
| IIIC2p | 5 (1.1) | 0 (0.0) | 5 (2.2) | 0 (0.0) | |
| IVA | 8 (1.8) | 0 (0.0) | 8 (3.5) | 0 (0.0) | |
| IVB | 94 (20.8) | 0 (0.0) | 0 (0.0) | 94 (100.0) | |
| Missing | 1 (0.2) | 1 (0.8) | 0 (0.0) | 0 (0.0) | |
| ECOG performance status | |||||
| 0 | 272 (60.0) | 101 (75.9) | 116 (51.3) | 55 (58.5) | <0.0001 |
| 1 | 16 (3.5) | 0 (0.0) | 7 (3.1) | 9 (9.6) | |
| 2 | 6 (1.3) | 0 (0.0) | 1 (0.4) | 5 (5.3) | |
| 3 | 2 (0.4) | 0 (0.0) | 0 (0.0) | 2 (2.1) | |
| Missing | 157 (34.7) | 32 (24.1) | 102 (45.1) | 23 (24.5) | |
| Current or former smoker | |||||
| No | 251 (55.4) | 74 (55.6) | 121 (53.5) | 56 (59.6) | 0.7593 |
| Yes | 174 (38.4) | 53 (39.8) | 89 (39.4) | 32 (34.0) | |
| Not reported | 28 (6.2) | 6 (4.5) | 16 (7.1) | 6 (6.4) | |
| Histology | |||||
| Pure | 307 (67.8) | 69 (51.9) | 157 (69.5) | 81 (86.2) | <0.0001 |
| Mixed | 146 (31.4) | 64 (48.1) | 69 (30.5) | 13 (14.0) | |
| Histology | |||||
| HGNEC | 72 (15.9) | 18 (13.5) | 28 (12.4) | 26 (27.7) | 0.0206 |
| Large cell | 70 (15.5) | 25 (18.8) | 31 (13.7) | 14 (14.9) | |
| Small cell | 305 (67.3) | 88 (66.2) | 163 (72.1) | 54 (57.4) | |
| Small and large cell | 6 (1.3) | 2 (1.5) | 4 (1.8) | 0 (0.0) | |
| Pelvic node status† | |||||
| Negative | 245 (54.1) | 133 (100.0) | 77 (34.1) | 35 (37.2) | <0.0001 |
| Positive | 207 (45.7) | 0 (0.0) | 148 (65.5) | 59 (62.8) | |
| Missing | 1 (0.2) | 0 (0.0) | 1 (0.4) | 0 (0.0) | |
| Tumor size (cm) | |||||
| ≤2 | 108 (23.8) | 83 (62.4) | 20 (8.8) | 5 (5.3) | |
| >2–≤4 | 105 (23.2) | 49 (36.8) | 43 (19.0) | 13 (13.8) | |
| >4 | 227 (50.1) | 0 (0.0) | 158 (69.9) | 69 (73.4) | |
| Not reported | 13 (2.9) | 1 (0.8) | 5 (2.2) | 7 (7.4) | <0.0001 |
| Pregnant at diagnosis | |||||
| Yes | 20 (4.4) | 7 (5.3) | 11 (4.9) | 2 (2.1) | 0.4971 |
| No | 432 (95.4) | 126 (94.7) | 214 (94.7) | 92 (97.9) | |
| Missing | 1 (0.2) | 0 (0.0) | 1 (0.4) | 0 (0.0) | |
| Post partum at diagnosis | |||||
| Yes | 14 (3.1) | 4 (3.0) | 5 (2.2) | 5 (5.3) | 0.3236 |
| No | 438 (96.7) | 129 (97.0) | 220 (97.3) | 89 (94.7) | |
| Missing | 1 (0.2) | 0 (0.0) | 1 (0.4) | 0 (0.0) |
*Results reported as number of patients (%) unless otherwise specified.
†Nodal positivity (pelvic and/or para-aortic) based on pathology report for patients who underwent surgery (sentinel lymph node biopsy and/or pelvic lymphadenectomy and/or para-aortic lymphadenectomy) and images for patients who did not undergo surgery.
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; HGNEC, high-grade neuroendocrine carcinoma.